Standard quality house dust mite sublingual immunotherapy tablets (SLIT) maintained asthma control while reducing the need for inhaled corticosteroids in patients aged 14 years or older, according to recently published data.
Researchers at Copenhagen University Hospital Gentofte, Denmark, randomly assigned 604 patients aged 14 years or older with house dust mite allergic rhinitis and mild-to-moderate asthma in a 1:1:1:1 fashion to one of three active doses (6, 3 or 1) of standard quality (SQ) house dust mite (HDM) sublingual immunotherapy (SLIT) or placebo.
Primary data indicated that the daily inhaled corticosteroids (ICS) dose was reduced from baseline by 208 mcg (adjusted mean) for 6 SQ-HDM and 126 mcg for placebo; demonstrated a reduction of ICS by 81 mcg daily for 6 SQ-HDM vs. placebo (P=.004), according to researchers.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management
- Edition Archive